pyrazines has been researched along with Benign Neoplasms in 295 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (4.07) | 18.2507 |
| 2000's | 132 (44.75) | 29.6817 |
| 2010's | 131 (44.41) | 24.3611 |
| 2020's | 20 (6.78) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X; Nie, S; Song, Y; Wu, F; Wu, J; Yao, Y; Zhou, C | 1 |
| Huang, PH; Ji, Y; Myers, A; Woolfenden, S | 1 |
| Donnelly, L; Elghobashi-Meinhardt, N; Li, X; Liu, Y; Long, T; Qi, X; Sun, Y; Wang, B; Zhou, RW | 1 |
| Huan, S; Li, Z; Liao, S; Liu, S; Song, G; Wang, Y; Yin, X; Zhang, XB; Zhang, Y | 1 |
| Angius, G; Bianco, V; Stati, V; Tomao, F; Tomao, S; Vici, P | 1 |
| Duarte, D; Esteves da Silva, JCG; Ferreira, PJO; González-Berdullas, P; Magalhães, CM; Núnez-Montenegro, A; Pinto da Silva, L; Rodríguez-Borges, JE; Vale, N | 1 |
| Hope, JM; King, MR; Lopez-Cavestany, M; Reinhart-King, CA; Wang, W | 1 |
| Bell-McGuinn, K; Bendell, JC; Bischoff, HG; Campbell, R; Farrington, DL; Hwang, J; Hynes, S; Iversen, P; Pitou, C; Reinhardt, HC; Thomas, M; Wang, X; Zander, T | 1 |
| Baturevych, A; Clouser, CR; Hause, RJ; Johnstone, TG; Jones, JC; Krejsa, CM; Ponce, R; Ports, MO; Qin, JS; Ragan, SP; Salmon, RA | 1 |
| Andrs, M; Gorecki, L; Korabecny, J; Rezacova, M | 1 |
| Fenioux, C; Funck-Brentano, C; Gligorov, J; Gougis, P; Solas, C; Spano, JP; Veyri, M | 1 |
| Love, AC; Prescher, JA | 1 |
| Falk, M; Hendriks, BS; Jansen, M; Terranova, N | 1 |
| Macip, S; Massip-Salcedo, M; Qusairy, Z; Rada, M | 1 |
| Baird, JD; Bedard, PL; Branstrom, A; Colacino, J; Gao, L; Goodwin, E; Infante, J; Kaushik, D; Kong, R; Laskin, OL; O'Keefe, K; O'Mara, E; Shapiro, GI; Spiegel, RJ; Weetall, M | 1 |
| Panchal, S; Patel, B; Shah, K | 1 |
| Cash, T; Fox, E; Liu, X; Minard, CG; Reid, JM; Scheck, AC; Weigel, BJ; Wetmore, C | 1 |
| Argilés, G; Connolly, RM; de Jonge, M; Dobson, JR; Garralda, E; Giannakis, M; Janku, F; Ji, Y; McLaughlin, ME; Moody, SE; Morawiak, J; Rodon, J; Seroutou, A; Smith, DC; Vaishampayan, U | 1 |
| D'Andrea, AD; de Jonge, A; Do, KT; Gannon, C; Hedglin, J; Kelland, S; Kochupurakkal, B; Lazaro, JB; Parmar, K; Powers, A; Quinn, N; Shapiro, GI; Vuong, L | 1 |
| Bellanti, F; Buil-Bruna, N; Edlund, H; Liu, H; Sharma, S; Tomkinson, H; Vishwanathan, K; Ware, J | 1 |
| Bae, M; Blacklow, SC; Cao, R; Cuny, GD; Donovan, KA; Fischer, ES; Henke, MT; Lumpkin, RJ; Ray, SS; Rogers, JM; Seegar, TCM; Vemulapalli, V | 1 |
| Bai, R; Chen, N; Fan, Y; Hao, LJ; Hao, Y; Li, GS; Liu, YJ; Mao, Y; Shi, C; Wang, YJ; Xia, GX; Yu, JX; Zhang, CC; Zhang, J; Zhang, LD; Zhao, F | 1 |
| Cheng, L; Fan, Q; Hao, T; Li, D; Lv, H; Ma, H; Peng, J; Shao, M; Zhao, C; Zong, X | 1 |
| Lum, L; Zhang, LS | 1 |
| Gao, P; Hao, X; Liu, X; Xu, H; Zhan, P; Zou, J | 1 |
| Fernandez-Capetillo, O; Lecona, E | 1 |
| Chen, S; Hu, J; Liao, C; Mao, R; Yang, H; Zhao, J | 1 |
| Chen, M; Li, D; Qian, J; Qin, A; Tang, BZ; Wang, Y; Xie, W; Zebibula, A | 1 |
| Beckmann, RP; Blosser, W; Cole, KA; Dowless, M; Erickson, SW; Gorlick, R; Hawkins, DS; Houghton, PJ; Iversen, PW; Kang, MH; Kolb, EA; Krytska, K; Kurmasheva, RT; Lin, AB; Lowery, CD; Maris, JM; Renschler, M; Reynolds, CP; Rubin, BP; Smith, MA; Stancato, LF; Stephens, JR; Teicher, BA; VanWye, AB | 1 |
| Choi, J; Chung, SH; Ham, YJ; Jang, SY; Kang, SJ; Kim, YH; Lee, JW; Min, KH; Suh, KH | 1 |
| Cheon, S; Cho, D; Cho, DJ; Hur, DY; Kim, DY; Kim, KE; Park, HJ; Park, JM; Park, S | 1 |
| Ai, HW; Chen, M; Wu, T; Yeh, HW | 1 |
| Iikubo, K; Iwai, Y; Kamikawa, A; Kondoh, Y; Kurosawa, K; Matsuya, T; Moritomo, A; Shimada, I; Tomiyama, H | 1 |
| Frigault, MM; Gan, HK; Hua, Y; Lickliter, JD; Millward, M; Morgan, S; Qi, C; Sai, Y; Su, W; Wang, J; Yang, L; Zhang, L | 1 |
| Hur, D; Jin, DH; Kim, D; Kim, JE; Lee, WJ; Wu, TC | 1 |
| Gillet, JP; Gottesman, MM; Varma, S | 1 |
| Mita, N; Murata, S | 2 |
| Hu, Y; Wu, P; Zhang, J | 1 |
| Ames, MM; Erlichman, C; Hendrickson, AE; Menefee, M; Northfelt, D; Qin, R; Satele, D; Schenk, E; Toft, DO | 1 |
| Barmade, MA; Bothara, KG; Miniyar, PB; Murumkar, PR; Patil, PS | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kikuchi, J; Nobuyoshi, M; Ohki, M; Park, SY; Shibayama, N; Sugiyama, K; Wada, T; Yamada, S | 1 |
| Adjei, AA; Bible, KC; Croghan, G; Erlichman, C; Jett, J; Kaufmann, SH; Kumar, SK; Markovic, SN; Marks, R; Molina, J; Moynihan, T; Qin, R; Quevedo, F; Richardson, R; Tan, A | 1 |
| Alberti, D; Bailey, HH; Espinoza-Delgado, I; Hoang, T; Holen, KD; Kim, K; Kolesar, JM; Schelman, WR; Seo, S; Traynor, AM; Wilding, G; Wright, JJ | 1 |
| Brüning, A; Friese, K; Rahmeh, M | 1 |
| Beric, A; Hochster, H; Ivy, P; Joseph, SO; Kobrinsky, B; Liebes, L; Malankar, A; Muggia, F | 1 |
| Barda, D; Barnard, D; Blosser, W; Clawson, D; Cox, K; Diaz, H; Guo, S; King, C; Marshall, M | 1 |
| Alberti, D; Ames, MM; Bailey, HH; Deming, DA; Eickhoff, J; Espinoza-Delgado, I; Kolesar, JM; Marnocha, R; McGovern, RM; Ninan, J; Reid, JM; Schelman, WR; Wilding, G; Wright, J | 1 |
| Alberti, D; Ames, MM; Attia, S; Bailey, HH; Eickhoff, J; Espinoza-Delgado, I; Hoang, T; Holen, KD; Jiang, Z; Kolesar, JM; Marnocha, R; McGovern, RM; Reid, JM; Schelman, WR; Traynor, AM; Wilding, G; Wright, JJ | 1 |
| Boral, AL; Brenner, JC; Carey, TE; Che, J; Cheng, D; Cheng, J; Flynn, S; Graham, MP; Guo, G; Harris, JL; Hsieh, MH; Kasibhatla, S; Kowal, C; Li, AG; Li, C; Li, J; Liu, J; McLaughlin, ME; McNamara, P; Ng, N; Pan, S; Petruzzelli, L; Pferdekamper, A; Phung, V; Schuller, AG; Schultz, PG; Seidel, HM; Sellers, WR; Steffy, A; Sun, F; Tompkins, C; Vanasse, G; Villarroel, MC; Wang, T; Wang, Y; Wu, X | 1 |
| Anchoori, RK; Chen, X; Hung, CF; Jiang, R; Karanam, B; Matsui, W; Orlowski, RZ; Peng, S; Roden, RB; Rudek, MA; Tanno, T; Walters, KJ; Wang, JW; Zhao, M | 1 |
| da Silva, RS; Fukuto, JM; Heinrich, TA; Tedesco, AC | 1 |
| Shang, Z; Wei, J; Xiao, Y; Yin, J | 1 |
| Anderson, LM; Biswas, D; Holland, RJ; Ji, X; Keefer, LK; Kim, Y; Kumari, V; Luthers, CE; Maciag, AE; Morris, NL; Saavedra, JE; Sehareen, WS | 1 |
| Dudem, S; Jain, N; Kalivendi, SV; Vangala, JR | 1 |
| Abraham, TL; Cassidy, KC; Chana, E; Hynes, SM; Jost, LM; Mitchell, MI; Palmieri, MD; Rehmel, JF; Wickremsinhe, ER | 1 |
| Einsele, H | 1 |
| Chambers, JE; Clarke, HJ; Liniker, E; Marciniak, SJ | 1 |
| Barnard, D; Calles, A; Calvo, E; Chen, VJ; Diaz, HB; Dickgreber, N; Huber, L; Hynes, SM; Iversen, P; Kays, L; Kumm, E; Lin, AB; Marshall, M; Merzoug, FF; Ohnmacht, U; Sebastian, M; Voss, B; Wehler, T | 1 |
| Eriksson, E; Hou, M; Jahnukainen, K; Meinhardt, A; Sävendahl, L; Söder, O; Svechnikov, K | 1 |
| Chen, D; Dou, QP; Guan, F; Wang, H; Yang, H | 1 |
| Yagi, H | 1 |
| de Vries, EG; Fehrmann, RS; Franke, L; Krajewska, M; Labib, S; Schoonen, PM; van Vugt, MA | 1 |
| Alam, S; Carden, CP; Gedrich, R; Johnson, FM; Jones, RL; Kaye, SB; Kim, ES; Lippman, SM; Nava-Parada, P; Poondru, S; Simantov, R; Stephens, AW | 1 |
| Berlin, J; Chan, E; Evans, TR; Gedrich, R; Gilbert, J; Goff, L; Lindsay, CR; Poondru, S; Puzanov, I; Simantov, R; Sosman, J; Stephens, A | 1 |
| Reiter, RJ; Vriend, J | 1 |
| Chen, P; Chen, Z; Gao, X; Hou, J; Hu, R; Ruan, K; Tao, Y; Wang, H; Yang, M; Yu, T; Zhang, T; Zhang, Y | 1 |
| Chu, SH; Cleeland, CS; Geng, Y; Lee, ES; Lee, YJ; Wang, XS | 1 |
| Chandler, J; Decker, R; Hynes, SM; Mitchell, M; Ott, J; Wickremsinhe, E; Zhang, W | 1 |
| Huang, Z; Liu, P; Shu, Y; Wu, Y; Xu, J; Zhou, X; Zhu, W | 1 |
| Yee, D | 1 |
| Morrison, VA | 1 |
| Chu, F; Gong, Y; Gu, S; Lei, H; Li, G; Wang, M; Wang, P; Xu, B; Xu, K; Xu, X; Zhang, H; Zhang, Y | 1 |
| Mitsiades, CS | 1 |
| Apuy, J; Bissonette, R; Canan, SS; Cathers, BE; Fultz, KE; Gamez, JC; Ghoreishi, K; Hickman, M; Khambatta, G; Leisten, J; Moghaddam, MF; Mortensen, DS; Narla, RK; Packard, G; Peng, SX; Perrin-Ninkovic, S; Raymon, HK; Richardson, S; Sankar, S; Shi, T; Tong, Z; Tran, T; Worland, P; Xu, S; Xu, W; Yang, WQ; Zhao, J | 1 |
| Foote, KM; Lau, A; Nissink, JW | 1 |
| Barda, D; Barnard, D; Beckmann, R; Blosser, W; Dempsey, J; Diaz, HB; King, C; Marshall, MS; McNeely, S | 1 |
| Doi, T; Fuse, N; Hynes, SM; Lin, AB; Matsubara, N; Naito, Y; Nakamura, T; Shitara, K; Uenaka, K; Yoshino, T | 1 |
| Bedard, PL; Bendell, JC; Cleary, JM; Houk, B; Infante, JR; Jones, SF; Pandya, SS; Pierce, KJ; Razak, AR; Roberts, WG; Shapiro, GI; Shreeve, SM; Siu, LL | 1 |
| Bronsart, LL; Contag, CH; Stokes, C | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Chaves, J; Conklin, E; Gill, S; Nagata, M; Parker, B; Poondru, S; Singh, M; Yuen, G | 1 |
| Du, Z; Zhang, M; Zhang, Y | 1 |
| Chavan, A; Fukuoka, K; Horobin, J; Iwasa, T; Keegan, M; Nakagawa, K; Padval, M; Shimizu, T; Takeda, M; Vaickus, L; Yoshida, T | 1 |
| Bauer, TM; Bendell, J; Burris, H; Golden, L; Hong, D; Hynes, S; Infante, J; Janku, F; Johnson, FM; Jones, S; Kurzrock, R; Lin, AB; Lin, J; Naing, A; Nguyen, LM; Piha-Paul, S | 1 |
| Esteves da Silva, JC; Magalhães, CM; Pinto da Silva, L | 1 |
| Ide, S; Kojima, S; Nakanishi, Y; Nishino, K; Tanamachi, K; Tanuma, S; Tsukimoto, M | 1 |
| Carvalho, LA; Kantar, RS; Lashgari, G; Lewandrowski, GK; Tabet, EI; Tannous, BA | 1 |
| Becerra, C; Bence Lin, A; Braiteh, F; Calvo, E; Galsky, MD; Hurt, K; Hynes, SM; Jameson, G; Lin, J; McKane, S; McWilliams, R; Richards, D; Von Hoff, D; Wickremsinhe, ER | 1 |
| Hashimoto, K; Inazuka, M; Ishikawa, T; Sumi, H; Yabuki, M; Yoshida, S | 1 |
| Chen, D; Dou, QP; Landis-Piwowar, KR; Milacic, V; Yang, H | 1 |
| Cvek, B; Dvorak, Z | 2 |
| McConkey, DJ | 1 |
| Brandes, G; Buer, J; Carlomagno, T; Frank, R; Geffers, R; Gossler, A; Gütgemann, I; Kalesse, M; Kubicka, S; Malek, NP; Manns, MP; Menche, D; Nickeleit, I; Sasse, F; Sörensen, I; Steinmetz, H; Zender, S | 1 |
| Sayers, T | 1 |
| Chow, L; Eckhardt, SG; Gore, L; Lieu, C; Morrow, M; O'Bryant, CL; Pierson, AS; Tran, ZV; Wright, JJ | 1 |
| de Jong, S; de Vries, EG; Oldenhuis, CN; Stegehuis, JH; Walenkamp, AM | 1 |
| De Meester, I; Lambeir, AM; Scharpé, S | 1 |
| Clarke, PA; Powers, MV; Workman, P | 1 |
| Bachmann, AS | 1 |
| Littlehales, C | 1 |
| Munday, R; Zhang, Y | 1 |
| Cavaletti, G; Gilardini, A; Marmiroli, P | 1 |
| Chen, W; Hai, T; Mora-Jensen, H; Perez-Galan, P; Ron, D; Trenkle, W; Wang, Q; Weniger, MA; Wiestner, A; Wolford, C; Ye, Y | 1 |
| Hunter, P | 1 |
| Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L | 1 |
| Tsukamoto, S; Yokosawa, H | 1 |
| Dudek, AZ; Franklin, M; Greeno, EW; Kratzke, RA; Kumar, P; Lesniewski-Kmak, K; Pandey, ON; Shehadeh, NJ | 1 |
| Berndt, N; Guida, WC; Kazi, A; Lawrence, H; McLaughlin, ML; Sebti, SM; Springett, GM; Yip, RM | 1 |
| Rolfe, M; Smith, PG; Soucy, TA | 1 |
| Emadi, A; Ghosh, N | 1 |
| Testa, U | 1 |
| Bolen, J | 1 |
| Schiff, D; van den Bent, MJ; Wen, PY | 1 |
| Gastl, G; Gunsilius, E; Kern, J; Sarg, B; Steurer, M; Untergasser, G; Zenzmaier, C | 1 |
| Grant, S | 1 |
| Bekaii-Saab, T; Byrd, JC; Culler, K; Grever, MR; Lesinski, GB; Lucas, DM; Ramaswamy, B; Ruppert, AS; Schaaf, LJ; Shapiro, CL; Wilkins, D; Wright, JJ; Young, DC | 1 |
| Fishbein, JC; Holland, R; Kensler, TW; Navamal, M; Velayutham, M; Zweier, JL | 1 |
| Almasan, A; Banerjee, AK; Fairchild, RL; Gasparian, AV; Gorbachev, AV; Gudkov, AV; Gurova, KV; Komarov, AP; Neznanov, N; Neznanova, L | 1 |
| Babcock, T; Bannerman, B; Cao, Y; Hatsis, P; Kupperman, E; Robertson, R; Silva, MD; Terkelsen, J; Williamson, MJ; Xia, C; Yu, L | 1 |
| Berkers, CR; Ovaa, H | 1 |
| Colland, F | 1 |
| Adamo, V; Bronte, G; Cicero, G; Fulfaro, F; Gebbia, N; Rizzo, S; Russo, A | 1 |
| Calinski, D; Chanan-Khan, AA; Li, F; Ling, X; Zhou, M | 1 |
| Chatta, G; Chen, E; Cooper, M; Egorin, M; Karol, M; Neuwirth, R; Rader, M; Ramalingam, S; Ramanathan, RK; Riordan, W; Trepicchio, W; Venkatakrishnan, K; von Moltke, L | 1 |
| Dick, LR; Fleming, PE | 1 |
| Chen, C; Eckhardt, SG; Pugh, TJ; Raben, D; Rabinovitch, R; Rusthoven, KE; Swing, R | 1 |
| Chow, W; Cristea, M; Doroshow, JH; Frankel, P; Gaur, S; Koczywas, M; Lim, D; Luu, T; Margolin, K; Morgan, RJ; Somlo, G; Yen, Y | 1 |
| Bannerman, B; Berger, A; Blank, J; Bolen, J; Bruzzese, F; Cao, Y; Dick, L; Fitzgerald, M; Fleming, P; Garcia, K; Hales, P; Kupperman, E; Lee, EC; Liu, J; Manfredi, M; Rolfe, M; Tsu, C; Yang, Y; Yu, J; Yu, L | 1 |
| Aldana-Masankgay, G; Cho, CH; Fan, D; Lee, CW; Milani, M; Sakamoto, KM; Sung, JJ; Wu, K; Wu, WK; Yu, J | 1 |
| Buffa, F; Hammond, E; Harris, AL; Mellor, HR; Milani, M; Pike, L; Pires, I; Ragoussis, I; Rzymski, T; Winchester, L | 1 |
| Hirai, T; Yamaguchi, Y; Yamamura, M | 1 |
| Wright, JJ | 1 |
| Aggarwal, BB; Kannappan, R; Yadav, VR | 1 |
| Atrash, B; Bavetsias, V; Bayliss, R; Blagg, J; Bouloc, N; Brown, N; Faisal, A; Kosmopoulou, M; Large, JM; Linardopoulos, S; Matteucci, M; McDonald, E; Reynisson, J; Sun, C | 1 |
| Cheng, B; Cheung, YK; Lee, SM | 1 |
| Cohen, N; Klein, S; Kravchenko-Balasha, N; Levitzki, A; Mizrachy-Schwartz, S | 1 |
| Bommakanti, SV; Dudek, AZ; Gada, PD; Khatri, A; Kirstein, MN | 1 |
| Chen, D; Dou, QP; Frezza, M; Kanwar, J; Schmitt, S | 1 |
| Bittner, MA; Cooke, A; Dong, H; Foreman, K; Gokhale, PC; Ji, Q; Jin, M; Kleinberg, A; Landfair, D; Mak, G; Mulvihill, KM; Mulvihill, MJ; O'Connor, M; Pachter, JA; Rosenfeld-Franklin, M; Siu, KW; Wild, R; Yao, Y | 1 |
| Chang, TC; Ko, BS; Liou, JY | 1 |
| Cleary, MA; Laver, T; McMahon, S; Mellert, H; Schelter, JM; Sotillo, E; Thomas-Tikhonenko, A | 1 |
| Basso, AD; Esposite, S; Gray, K; Hicklin, DJ; Kerekes, AD; Kirschmeier, P; Lee, S; Liang, L; Liu, M; Monsma, FJ; Ponery, A; Smith, EB; Tagat, JR; Tevar, S; Xiao, Y; Yu, T; Zhang, Y | 1 |
| Gartel, AL; Pandit, B | 1 |
| Arnold, LD; Buck, E; Cooke, A; Foreman, K; Gibson, NW; Ji, QS; Landfair, D; Mulvihill, MJ; O'Connor, M; Pirritt, C; Rosenfeld-Franklin, M; Sun, Y; Yao, Y | 1 |
| Davies, A; Egorin, MJ; Hamilton, A; Ivy, SP; Leal, TB; Lenz, HJ; LoRusso, PA; Mani, S; Mier, J; Mulkerin, D; Neuwirth, R; Ramanathan, RK; Remick, SC; Sarantopoulos, J; Shibata, S; Takimoto, CH; Venkatakrishnan, K; von Moltke, L; Wright, JJ | 1 |
| Meerang, M; Ramadan, K | 1 |
| Cheung, YK; Hershman, DL; Lee, SM; Leonard, JP; Martin, P | 1 |
| Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M | 1 |
| Czyz, M; Duechler, M; Wilczynski, J | 1 |
| Sayers, TJ | 1 |
| Gounder, M; Kane, M; Karantza, V; Levinson, K; Lin, H; Lin, Y; Mehnert, JM; Moss, R; Poplin, E; Rubin, EH; Shih, WJ; Sovak, M; Stein, MN; Tan, AR; White, E | 1 |
| Curtit, E; Mansi, L; Viel, E; Vignot, S | 1 |
| Alfieri, A; Altamura, S; Brunetti, M; Bufali, S; Colaceci, F; Ferrigno, F; Filocamo, G; Fonsi, M; Gallinari, P; Hernando, JI; Jones, P; Kinzel, O; Malancona, S; Monteagudo, E; Orsale, MV; Palumbi, MC; Pucci, V; Rowley, M; Sasso, R; Scarpelli, R; Steinkühler, C | 1 |
| Altamura, S; Filocamo, G; Hernando, JI; Jones, P; Kinzel, O; Malancona, S; Rowley, M; Scarpelli, R; Steinkühler, C | 1 |
| Fulda, S | 1 |
| Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P | 1 |
| Bisonette, RR; Fultz, KE; Harris, R; Hickman, M; Khambatta, G; Lee, BG; Mortensen, DS; Perrin-Ninkovic, SM; Sankar, S; Shevlin, G | 1 |
| Molineaux, SM | 1 |
| Kaiser, M; Krahn, D; Ottmann, C | 1 |
| Duvic, M; Falchook, GS; Hong, DS; Kurzrock, R; Lim, J; Naing, A; Wheler, J | 1 |
| Wu, WK | 1 |
| Albarrán, M; Alfonso, P; Alvarez, RM; Bischoff, JR; Cebriá, A; Fominaya, J; García, AB; Hernández, AI; Link, W; Lorenzo, M; Martínez González, S; Oyarzabal, J; Pastor, J; Rabal, O; Rivero, V; Rodríguez-Arístegui, S; Varela, C | 1 |
| Dowlati, A; Esseltine, DL; Hamilton, A; Ivy, P; LoRusso, PM; Mani, S; Mulkerin, D; Neuwirth, R; Ramanathan, RK; Rudek, MA; Sarantopoulos, J; Shibata, SI; Takimoto, CH; Venkatakrishnan, K | 1 |
| Anthony, SP; Donehower, RC; Hurt, K; Hynes, SM; Iyengar, T; Lewandowski, K; McKane, S; Ramanathan, RK; Weiss, GJ; Westin, E | 1 |
| Backendorf, C; Lanz, HL; Noteborn, MH; Suijker, J | 1 |
| Grantab, RH; Tannock, IF | 1 |
| Ikeda, D; Masuda, T; Momose, I; Nomoto, A; Ohba, S; Tatsuda, D | 1 |
| Martinon, F | 1 |
| Cvek, B | 1 |
| Chowdhury, RD; Driscoll, JJ | 1 |
| Aguirre, E; Albarrán, MI; Alfonso, P; Barbacid, M; Bischoff, JR; Blanco-Aparicio, C; Cebrián, D; Cendón, E; Fominaya, J; García-Serelde, B; Gomez-Casero, E; Gonzalez-Granda, T; Hernández, AI; Link, W; Lorenzo, M; Martínez González, S; Mateos, G; Mulero, F; Oyarzabal, J; Pastor, J; Pizcueta, P; Rabal, O; Ramos-Lima, F; Varela, C | 1 |
| Ahern, CH; Ames, MM; Blaney, SM; Espinoza-Delgado, I; Horton, TM; Ingle, AM; McGovern, RM; Muscal, JA; Reid, JM; Thompson, PA; Weigel, BJ | 1 |
| Chan, CT; Chiosis, G; Gambhir, SS; Geller, R; Hoehne, A; Massoud, TF; Paulmurugan, R; Reeves, RE; Solow-Cordero, DE; Yaghoubi, SS | 1 |
| de Jong, S; de Wilt, LH; Jansen, G; Kroon, J; Kruyt, FA; Peters, GJ | 1 |
| Sun, Y; Zhao, Y | 1 |
| Shi, Y; Wu, ZH | 1 |
| Buac, D; Deshmukh, R; Dou, QP; Kona, FR; Mitra, B; Neslund-Dudas, C; Schmitt, S; Shen, M; Zhang, Z | 1 |
| Addepally, U; Chinta Rao, TS; Chiranjeevi, T; Patro, B; Saha, S; Venkata Ramana Reddy, Ch | 1 |
| Akintayo, A; Chen, Z; El-Rayes, B; Fanucchi, MP; Harvey, RD; Kauh, JS; Khuri, FR; Lewis, CM; Nadella, P; Owonikoko, TK; Ramalingam, SS; Rogatko, A; Shin, DM; Tighiouart, M | 1 |
| Adams, J; Aghajanian, C; Canales, C; Daud, A; Dizon, DS; Elliott, PJ; Hensley, ML; Miller, V; Pezzulli, S; Pien, CS; Sabbatini, P; Soignet, S; Spriggs, DR | 1 |
| Batist, G; Fotouhi-Ardakani, N; Hamilton, D | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Adams, J | 3 |
| Boehncke, WH; Elliott, PJ; Zollner, TM | 1 |
| Sudakin, DL | 1 |
| Cusack, JC | 1 |
| Lenz, HJ | 1 |
| Schoenfeldt, M; Wright, JJ; Zerivitz, K | 1 |
| Fujimori, T; Hino, S; Kawamata, H; Nakashiro, K; Omotehara, F; Uchida, D | 1 |
| Baumgartner, KJ; Bodreddigari, S; Curphey, TJ; Gange, SJ; Kensler, TW; Li, Y; Roebuck, BD; Sutter, TR; Yan, J | 1 |
| Goldman, B | 1 |
| Shiotsu, Y | 1 |
| D'Anneo, A; De Blasio, A; Giuliano, M; Tesoriere, G; Vento, R | 1 |
| Dees, EC; O'Neil, B; Orlowski, RZ; Voorhees, PM | 1 |
| Adams, J; Daliani, DD; Dieringer, P; Elliott, P; Esseltine, D; Kim, J; Logothetis, CJ; Madden, T; Millikan, RE; Nix, D; Pagliaro, L; Papandreou, CN; Perez, C; Petrusich, A; Pien, CS; Tu, SM; Wang, X; Yang, H | 1 |
| Adams, J; Kauffman, M | 1 |
| Bold, R | 1 |
| Capriotti, T | 1 |
| Lenz, HJ; Park, DJ | 1 |
| Adamson, PC; Berg, SL; Bernstein, M; Blaney, SM; Ginsberg, J; Horton, T; Kitchen, B; Krailo, M; Neville, K | 1 |
| Klener, P; Spicka, I | 1 |
| Korniluk, J; Wcisło, G; Wojtuń, S | 1 |
| Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG | 2 |
| Anderson, KC; Hideshima, T; Rajkumar, SV; Richardson, PG | 1 |
| Dalton, WS | 1 |
| Fleissner, C; Jakob, C; Kaiser, M; Krebbel, H; Possinger, K; Rosche, M; Schmid, P; Sezer, O; Zavrski, I | 1 |
| Murphy, WJ; Sayers, TJ | 1 |
| Adjei, AA; Alberti, D; Alberts, SR; Binger, K; Bruzek, L; Dy, GK; Erlichman, C; Hanson, LJ; Kaufmann, SH; Mandrekar, S; Marnocha, R; Pitot, HC; Thomas, JP; Tutsch, K; Wilding, G | 1 |
| Linder, S; Shoshan, MC | 1 |
| Albanell, J; Gascon, P; Mellado, B; Montagut, C; Ross, JS; Rovira, A | 1 |
| Adams, J; Boyden, J; Chachoua, A; Clark, JW; Eder, JP; Elliott, P; Farrell, K; Garcia-Carbonero, R; Hamilton, AL; Kinchla, N; Liebes, L; Muggia, FM; Pavlick, AC; Ryan, DP; Soma, V; Wright, J; Yee, H; Zeleniuch-Jacquotte, A | 1 |
| Musch, A | 1 |
| Facon, T; Giaccone, G; Khayat, D; Ludwig, H | 1 |
| Daniel, KG; Dou, QP; Kazi, A; Kuhn, DJ | 1 |
| Bay, JO; Blay, JY; Rixe, O; Spano, JP | 1 |
| Brooks, AD; Elliott, PJ; Murphy, WJ; Onksen, J; Ramirez, T; Sayers, TJ; Toh, U | 1 |
| Buisson, JP; Magdelenat, H; Monneret, C | 1 |
| Orlowski, RZ; Voorhees, PM | 1 |
| Brancolini, C; Demarchi, F | 1 |
| Fujimori, T; Imai, Y; Kawamata, H; Tachibana, M | 1 |
| Almuete, VI; Armstrong, DK; Baker, SD; Carducci, MA; Dinh, K; Donehower, RC; Lassiter, L; Messersmith, WA; Sullivan, RA; Wright, JJ | 1 |
| Mitsiades, C; Richardson, PG | 1 |
| Awada, A; de Castro, G | 1 |
| Albanell, J; Montagut, C; Rovira, A | 1 |
| Agnese, V; Bazan, V; Russo, A; Santini, D; Terrasi, M | 1 |
| Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ | 1 |
| Chu, H; Cole, SR; Nie, L | 1 |
| Amadori, S; Boccadoro, M; Caravita, T; de Fabritiis, P; Palumbo, A | 1 |
| Abrams, SI; Alvarez, G; Berg, M; Childs, R; Lundqvist, A; Schrump, DS; Suffredini, D | 1 |
| Fribley, A; Wang, CY | 1 |
| Hideshima, T; Yasui, H | 1 |
| Appleman, LJ; Clark, JW; Cusack, J; Eder, JP; Enzinger, PC; Fidias, P; Fishman, M; Kashala, O; Lynch, T; Ryan, DP; Supko, JG; Zhu, AX | 1 |
| Appleman, LJ; Clark, J; Cusack, JC; Dees, EC; Eder, JP; Fidias, P; Kashala, O; O'Neil, BH; Orlowski, RZ; Rocha Lima, CM; Ryan, DP; Supko, JG | 1 |
| Bernasconi, P; Calatroni, S; Crosetto, N; Dikic, I | 1 |
| Chan, TH; Chen, D; Dou, QP; Landis-Piwowar, KR; Milacic, V; Yan, B; Yang, H; Zhao, Y | 1 |
| Charalambous, A; Dhodapkar, MV; Jagannath, S; Mazumder, A; Spisek, R; Vesole, DH | 1 |
| Caponigro, F; Iaffaioli, RV; Milano, A | 1 |
| Bachmann, M; Bornhäuser, M; Rieber, EP; Schmitz, M; Straube, C; Wehner, R; Wendisch, M | 1 |
| Germain, D; Ishii, Y; Waxman, S | 1 |
| Giaccone, G; Honeywell, R; Kuenen, BC; Peters, GJ; Smit, EF; van de Velde, H; Voortman, J | 1 |
| Sayers, T; Shanker, A | 1 |
| Dhodapkar, MV; Spisek, R | 1 |
| Fishbein, JC; McCraken, J; Muthukumaran, RB; Sostaric, JZ; Velayutham, M; Zweier, JL | 1 |
| Davies, MJ | 1 |
| Singer, M | 1 |
| Moran, E; Nencioni, A | 1 |
| Fadeel, B; Sävendahl, L; Zaman, F | 1 |
| Agnese, V; Bazan, V; Cicero, G; Fratto, ME; Russo, A; Santini, D; Schiró, V; Tonini, G; Vincenzi, B | 1 |
| Puthalakath, H; Strasser, A | 1 |
| Chaudhary, U; Dunder, S; Green, M; Hayslip, J; Kraft, A; Meyer, M; Montero, AJ; Salzer, S; Sherman, C | 1 |
| Allievi, C; Berkers, C; Bernareggi, A; Bussolati, B; Camussi, G; Cassin, M; Coscia, M; Costa, G; de Feudis, P; di Giovine, S; Ferracini, R; Ferrero, D; Giai, V; Hunter, K; Inghirami, G; Jones-Bolin, S; Massaia, M; Neri, A; Nicoli, P; Ovaa, H; Palumbo, A; Peola, S; Pescalli, N; Pezzoni, G; Piva, R; Roato, I; Ruggeri, B; Strepponi, I; Tamagno, I; Williams, M; Zhao, H | 1 |
| Beckett, LA; Christensen, S; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, DH; Metzger, AS; Tanaka, M | 1 |
| Ames, E; Barao, I; Hallett, WH; Hudig, D; Motarjemi, M; Murphy, WJ; Sayers, TJ; Shanker, A; Tamang, DL | 1 |
| Chun, YS; Huang, LE; Lee, DS; Park, JW; Shin, DH | 1 |
| Adler, AS; Chang, HY; Lin, M; Nuyten, DS; Regev, A; Segal, E; van de Vijver, MJ; Wong, DJ | 1 |
| Ribatti, D; Roccaro, AM; Vacca, A | 1 |
| Alberti, D; Binger, K; Eickhoff, J; Geiger, P; Heideman, J; Kolesar, J; LoConte, NK; Marnocha, R; Thomas, JP; Utecht, K; Wilding, G | 1 |
| Carey, LA; Collichio, F; Collins, J; Dees, EC; Esseltine, D; Ivanova, A; Lindley, CM; O'Neil, BH; Orlowski, RZ; Riordan, WJ | 1 |
| Beard, M; Cohen, SJ; Engstrom, PF; Langer, CJ; Lewis, NL; McLaughlin, S; Meropol, NJ; Weiner, LM | 1 |
| Baritaki, S; Berenson, J; Bonavida, B; Daniels, TR; Jazirehi, AR; Palladino, M; Penichet, ML; Spandidos, DA; Suzuki, E; Umezawa, K | 1 |
| Carew, JS; Giles, FJ; Nawrocki, ST | 1 |
| Hahne, JC; Heider, U; Lamottke, B; Rademacher, J; Sezer, O; Sterz, J; Terpos, E; von Metzler, I | 1 |
| Ames, MM; Dhodapkar, MV; Reid, JM; Richardson, RL | 1 |
| Groopman, JD; Kensler, TW; Roebuck, BD | 1 |
| Helzlsouer, KJ; Kensler, TW | 1 |
| Balcerzak, SP; Kraut, EH; Supko, JG | 1 |
| Barham, HM; Chinje, EC; Inglis, R; Stratford, IJ | 1 |
| Markoglou, N; Wainer, IW | 1 |
| Benson, L; Einzig, AI; Grove, WR; Lathia, CD; Roca, J; Sklarin, NT; Thomas, S; Wiernik, PH | 1 |
| Clapper, ML; Szarka, CE | 1 |
| Bowling, MK; Donehower, RC; Grochow, LB; Long, GS; Noe, DA; Rowinsky, EK; Sartorius, SE | 1 |
| Curphey, TJ; Groopman, JD; Kensler, TW; Roebuck, BD; Sutter, TR | 1 |
| Choi, L; Eskens, FA; Harris, AL; Levitt, NC; Mather, R; Sparreboom, A; Verweij, J | 1 |
| An, WG; Blagosklonny, MV; Hwang, SG; Trepel, JB | 1 |
| Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD | 1 |
| Cheson, BD; Gore-Langton, RE; Hillsamer, VL; Wright, J | 1 |
| Eckhardt, SG; Hidalgo, M | 1 |
| Kim, ND; Lee, B; Lee, JW | 1 |
| Adams, J; Elliott, PJ | 1 |
| Bagnasco, M; Bennicelli, C; Camoirano, A; Cartiglia, C; De Flora, S; Egner, PA; Jacobson, LP; Kensler, TW; Qian, GS; Wang, JB; Zhang, BC; Zhu, YR | 1 |
| Choi, L; Denis, LJ; Eskens, FA; Foekens, JA; Harris, AL; Levitt, NC; Nakajima, M; O'Byrne, KJ; Owen, SJ; Propper, DJ; Steward, WP; Talbot, DC; Verweij, J; Wilner, S; Wood, JM | 1 |
| Elliott, PJ; Ross, JS | 1 |
| Garber, K | 1 |
| L'Allemain, G | 1 |
| Biswas, S; Das, SK; Gairola, CG | 1 |
| Dykes, DJ; Elliott, WL; Griswold, DP; Harrison, SD; Laster, WR; Leopold, WR; Temple, CG; Waud, WR | 1 |
110 review(s) available for pyrazines and Benign Neoplasms
| Article | Year |
|---|---|
Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development.
Topics: Checkpoint Kinase 1; Checkpoint Kinase 2; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2020 |
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Drug Discovery; Drug Synergism; Humans; Isoxazoles; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sulfones; Treatment Outcome | 2020 |
Seeing (and Using) the Light: Recent Developments in Bioluminescence Technology.
Topics: Animals; Channelrhodopsins; Firefly Luciferin; Imidazoles; Light; Luciferases; Luminescent Measurements; Microscopy, Fluorescence; Neoplasms; Optical Imaging; Pyrazines | 2020 |
Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antiviral Agents; Benzamides; COVID-19; COVID-19 Drug Treatment; Humans; Lung; Molecular Targeted Therapy; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrazines; Thrombosis | 2021 |
Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway.
Topics: Acyltransferases; Animals; Antineoplastic Agents; Drug Development; Drug Discovery; Enzyme Inhibitors; Humans; Membrane Proteins; Molecular Targeted Therapy; Neoplasms; Pyrazines; Pyridines; Wnt Signaling Pathway | 2021 |
Chemical Modulation of WNT Signaling in Cancer.
Topics: Acyltransferases; Humans; Membrane Proteins; Neoplasms; Pyrazines; Pyridines; Wnt Proteins; Wnt Signaling Pathway | 2018 |
Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Bacteria; Cardiovascular Diseases; Humans; Inflammation; Molecular Structure; Neoplasms; Neuroprotective Agents; Pyrazines | 2018 |
Targeting ATR in cancer.
Topics: Ataxia Telangiectasia Mutated Proteins; DNA Damage; Drug Development; Genomic Instability; Humans; Indoles; Isoxazoles; Molecular Targeted Therapy; Morpholines; Neoplasms; Nitroso Compounds; Oxazines; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinolines; Sulfonamides; Sulfoxides | 2018 |
Clinical and marketed proteasome inhibitors for cancer treatment.
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine | 2013 |
Unequivocal role of pyrazine ring in medicinally important compounds: a review.
Topics: Antineoplastic Agents; Antitubercular Agents; Diabetes Mellitus; Diuretics; Humans; Hypoglycemic Agents; Kidney; Mycobacterium tuberculosis; Neoplasms; Protein Kinase Inhibitors; Pyrazines | 2013 |
Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Heart Diseases; Humans; Incidence; Neoplasms; Odds Ratio; Pyrazines; Risk | 2014 |
Bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Pyrazines | 2014 |
Endoplasmic reticulum stress in malignancy.
Topics: Activating Transcription Factor 6; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Neoplasms; Neovascularization, Pathologic; Protein Folding; Protein Serine-Threonine Kinases; Pyrazines; Unfolded Protein Response | 2014 |
An analysis of the safety profile of proteasome inhibitors for treating various cancers.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Pyrazines | 2014 |
[Proteasome inhibitor].
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2014 |
Melatonin as a proteasome inhibitor. Is there any clinical evidence?
Topics: Animals; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Caspases; Humans; Melatonin; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2014 |
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.
Topics: Amitriptyline; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Carbamazepine; Central Nervous System; Cyclohexanols; Duloxetine Hydrochloride; Epothilones; Humans; Neoplasms; Neuralgia; Oxcarbazepine; Peripheral Nervous System Diseases; Pyrazines; Taxoids; Thalidomide; Thiophenes; Venlafaxine Hydrochloride; Vinca Alkaloids | 2015 |
Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Neoplasms; Pyrazines; Treatment Outcome | 2014 |
Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Infections; Boronic Acids; Bortezomib; Female; Humans; Immune Tolerance; Male; Middle Aged; Mycoses; Neoplasms; Opportunistic Infections; Pyrazines; Tumor Necrosis Factor-alpha; Virus Diseases | 2014 |
Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; DNA Damage; Humans; Isoxazoles; Molecular Conformation; Neoplasms; Pyrazines | 2015 |
Biomarker development in MET-targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinogenesis; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Clinical Trials as Topic; Gene Amplification; Hepatocyte Growth Factor; Humans; Imidazoles; Molecular Targeted Therapy; Mutation; Neoplasms; Patient Selection; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Signal Transduction; Triazines | 2016 |
Chemiluminescence and Bioluminescence as an Excitation Source in the Photodynamic Therapy of Cancer: A Critical Review.
Topics: Animals; Firefly Luciferin; Humans; Imidazoles; Luciferases, Firefly; Luciferases, Renilla; Luminescence; Luminescent Agents; Luminol; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrazines; Reactive Oxygen Species | 2016 |
Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
Topics: Acetylcysteine; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Curcumin; Humans; Neoplasms; Pentacyclic Triterpenes; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Triterpenes; Ubiquitin | 2008 |
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Topics: Alcohol Deterrents; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disulfiram; Drug Screening Assays, Antitumor; Forecasting; Humans; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thiocarbamates; Ubiquitin | 2008 |
Targeting TRAIL death receptors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Glioma; HLA-DR4 Antigen; HLA-DR5 Antigen; Humans; Neoplasms; Pyrazines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2008 |
DPP4 inhibitors for diabetes--what next?
Topics: Adamantane; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Hypoxia; Neoplasms; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Dithiolethiones for cancer chemoprevention: where do we stand?
Topics: Animals; Anticarcinogenic Agents; Chemoprevention; Humans; Models, Biological; Neoplasms; Pyrazines; Thiones; Thiophenes | 2008 |
Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Demyelinating Diseases; Humans; Myelin Sheath; Neoplasms; Neurotoxicity Syndromes; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2008 |
Not boring at all. Boron is the new carbon in the quest for novel drug candidates.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Boron; Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Carbon; Drug Design; Humans; Molecular Structure; Neoplasms; Protease Inhibitors; Pyrazines | 2009 |
Targeting the proteasome pathway.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Discovery; Humans; Lactones; Neoplasms; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Ubiquitin; Ubiquitin-Activating Enzymes; Ubiquitins | 2009 |
Proteasome inhibitors in cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Design; Drug Resistance, Neoplasm; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2009 |
Neurological adverse effects caused by cytotoxic and targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration | 2009 |
The therapeutic potential of deubiquitinating enzyme inhibitors.
Topics: Animals; Boronic Acids; Bortezomib; Endopeptidases; Humans; Molecular Structure; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Pyrazines; Ubiquitin; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Ubiquitination; Viruses | 2010 |
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2010 |
Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Endoribonucleases; Histone Deacetylase 6; Histone Deacetylases; Humans; JNK Mitogen-Activated Protein Kinases; Mechanistic Target of Rapamycin Complex 1; Membrane Proteins; Microtubule-Associated Proteins; Multiprotein Complexes; Neoplasms; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proteins; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Ubiquitinated Proteins; Ubiquitins | 2010 |
[Proteasome inhibitor].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Physiological Phenomena; Clinical Trials as Topic; Drug Design; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2010 |
Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Delivery Systems; Humans; Neoplasms; Pyrazines | 2010 |
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2011 |
Focal adhesion kinase as a therapeutic target of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2010 |
The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2011 |
Degradation-linked ubiquitin signal and proteasome are integral components of DNA double strand break repair: New perspectives for anti-cancer therapy.
Topics: Animals; Boronic Acids; Bortezomib; DNA Breaks, Double-Stranded; DNA Repair; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin | 2011 |
Novel proteasome inhibitors to overcome bortezomib resistance.
Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination | 2011 |
Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Cytokines; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1; Inflammation; Mice; Models, Biological; Neoplasms; NF-kappa B; Pyrazines; Signal Transduction; Transcription Factors; Tumor Suppressor Protein p53 | 2011 |
Targeting the extrinsic apoptosis signaling pathway for cancer therapy.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Receptors, Tumor Necrosis Factor; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2011 |
[EGFR/HER1: a target life].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins | 2012 |
Macrocyclic proteasome inhibitors.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Macrocyclic Compounds; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2011 |
Targeting endoplasmic reticulum signaling pathways in cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; HIV Protease Inhibitors; Humans; Neoplasms; Proteasome Endopeptidase Complex; Protein Folding; Pyrazines; Signal Transduction | 2012 |
Proteasome inhibitors.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.
Topics: Adenine; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Chloroquine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Synergism; Forecasting; Humans; Inclusion Bodies; Medical Oncology; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Translational Research, Biomedical; Ubiquitin | 2012 |
Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Neoplasms; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Cullin-RING Ligases as attractive anti-cancer targets.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cullin Proteins; Drug Design; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin-Protein Ligases | 2013 |
When ubiquitin meets NF-κB: a trove for anti-cancer drug development.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin; Ubiquitination | 2013 |
From bortezomib to other inhibitors of the proteasome and beyond.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines | 2013 |
The glutathione system in alkylator resistance.
Topics: Alkylating Agents; Anticarcinogenic Agents; Buthionine Sulfoximine; Enzyme Inhibitors; Ethacrynic Acid; Glutamate-Cysteine Ligase; Glutathione; Glutathione Synthase; Humans; Neoplasms; Pyrazines; Thiones; Thiophenes | 2002 |
Potential for proteasome inhibition in the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Proteasome inhibition: a new anti-inflammatory strategy.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Asthma; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Disease Models, Animal; Humans; Inflammation; Lysine; Models, Biological; Models, Chemical; Multienzyme Complexes; Multiple Sclerosis; Neoplasms; NF-kappa B; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Psoriasis; Pyrazines; Reperfusion Injury | 2003 |
Dietary aflatoxin exposure and chemoprevention of cancer: a clinical review.
Topics: Aflatoxins; Animals; Anticarcinogenic Agents; Biomarkers; Chlorophyllides; Diet; Humans; Neoplasms; Pyrazines; Reverse Transcriptase Inhibitors; Thiones; Thiophenes | 2003 |
The proteasome: structure, function, and role in the cell.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Disease Models, Animal; Humans; Multienzyme Complexes; Neoplasms; Polyubiquitin; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multienzyme Complexes; Multiple Myeloma; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Clinical update: proteasome inhibitors in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Drug Interactions; Humans; Microfilament Proteins; Multienzyme Complexes; Muscle Proteins; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53 | 2003 |
Vesnarinone: a differentiation-inducing anti-cancer drug.
Topics: Animals; Antineoplastic Agents; Apoptosis; Humans; Mice; Neoplasms; Pyrazines; Quinolines; Repressor Proteins | 2003 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Leupeptins; Models, Biological; Multienzyme Complexes; Neoplasms; Peptide Hydrolases; Phenotype; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
The proteasome as a target for cancer therapy.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Catalysis; Clinical Trials as Topic; Cysteine Endopeptidases; Enzyme Inhibitors; Humans; Models, Biological; Multienzyme Complexes; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2003 |
Development of the proteasome inhibitor Velcade (Bortezomib).
Topics: Boronic Acids; Bortezomib; Cell Survival; Clinical Trials as Topic; Cysteine Endopeptidases; Drug Design; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin-Activating Enzymes | 2004 |
New oncology strategy: molecular targeting of cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cetuximab; Cysteine Endopeptidases; ErbB Receptors; Gefitinib; Genetics, Medical; Humans; Medical Oncology; Molecular Biology; Multienzyme Complexes; Neoplasms; Neovascularization, Pathologic; Nurse's Role; Oncology Nursing; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
The role of proteasome inhibitors in solid tumors.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
[The role of proteasome in pathophysiology of cancer cachexia].
Topics: Boronic Acids; Bortezomib; Cachexia; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Proteasome inhibition in the treatment of cancer.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Cyclins; Drug Evaluation, Preclinical; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2005 |
Proteasome inhibition as a novel therapeutic target in human cancer.
Topics: Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2005 |
The proteasome.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Neoplasms; NF-kappaB-Inducing Kinase; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Pyrazines; Structure-Activity Relationship | 2004 |
Proteasome: an emerging target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Substrate Specificity; Treatment Outcome | 2005 |
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Humans; Membrane Glycoproteins; Neoplasms; Protease Inhibitors; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2006 |
Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Humans; Lysosomes; Neoplasms; Pyrazines | 2005 |
Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Proteasome Inhibitors; Pyrazines | 2005 |
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Models, Molecular; Multiple Myeloma; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2005 |
Anti-angiogenic and anti-tumor properties of proteasome inhibitors.
Topics: Acetylcysteine; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Proteasome inhibition: a new approach for the treatment of malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Primates; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rodentia | 2005 |
[A new therapy with bortezomib, an oncologic medicinal product of the year 2004].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin | 2005 |
The proteasome and proteasome inhibitors in cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Humans; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mitochondria; Mitochondrial Proteins; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Tumor Necrosis Factor; Ubiquitin; Ubiquitin-Protein Ligases | 2005 |
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2006 |
Differentiation-inducing therapy for solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Humans; Neoplasms; PPAR gamma; Pyrazines; Quinolines | 2006 |
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Forecasting; Humans; Neoplasms; Proteasome Inhibitors; Pyrazines | 2005 |
Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Farnesyltranstransferase; Humans; Immunologic Factors; Lenalidomide; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Thalidomide | 2006 |
The proteasome: a novel target for anticancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Dexamethasone; Drug Design; Humans; Multiple Myeloma; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Randomized Controlled Trials as Topic; Ubiquitin | 2006 |
Apoptosis: a relevant tool for anticancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Capsid Proteins; Humans; Inhibitor of Apoptosis Proteins; Ligands; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasms; Pyrazines; Receptors, Death Domain; Sulindac; Survivin; TNF-Related Apoptosis-Inducing Ligand | 2006 |
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Lymphoma; Multiple Myeloma; Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome | 2006 |
[Proteasome inhibitor bortezomib as an anticancer drug].
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Clinical Trials as Topic; Cytokines; Heat-Shock Proteins; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
Targeting ubiquitin in cancers.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Communication; Cell Cycle; Genetic Therapy; Heat-Shock Proteins; Humans; Lactones; Neoplasms; Pyrazines; Pyrroles; Ubiquitin | 2006 |
The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catechin; Clinical Trials as Topic; Curcumin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Genistein; Humans; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Resveratrol; Stilbenes; Structure-Activity Relationship; Ubiquitin | 2006 |
The proteasome: a worthwhile target for the treatment of solid tumours?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2007 |
Targeting the ubiquitin-proteasome pathway in cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cyclin D1; Humans; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2007 |
Sensitizing tumor cells to immune-mediated cytotoxicity.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Humans; Immune System; Immunotherapy; Killer Cells, Natural; Ligands; Neoplasms; Proteasome Inhibitors; Pyrazines; Tumor Necrosis Factor-alpha | 2007 |
Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Dendritic Cells; Heat-Shock Proteins; Humans; Models, Biological; Neoplasms; Pyrazines; T-Lymphocytes | 2007 |
Management of novel therapeutics' side effects: a nurse-centric model.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Models, Nursing; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Advocacy; Patient Education as Topic; Pyrazines; Thalidomide | 2007 |
The role of proteasome in malignant diseases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome; Ubiquitin | 2007 |
Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Pyrazines | 2007 |
Bortezomib in the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Patents as Topic; Proteasome Inhibitors; Pyrazines; Signal Transduction | 2006 |
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Mitochondria; Neoplasms; Pyrazines; Reactive Oxygen Species; TNF-Related Apoptosis-Inducing Ligand | 2008 |
The potential of proteasome inhibitors in cancer therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Salvage Therapy; Ubiquitin; Ubiquitination | 2008 |
Carcinogen-DNA and protein adducts as intermediate biomarkers for human chemoprotection trials.
Topics: Aflatoxins; Animals; Anticarcinogenic Agents; Biomarkers, Tumor; Carcinogens; DNA; Humans; Liver Neoplasms, Experimental; Neoplasms; Proteins; Pyrazines; Thiones; Thiophenes | 1994 |
Cancer chemoprotection by oltipraz: experimental and clinical considerations.
Topics: Animals; Anticarcinogenic Agents; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Female; Humans; Male; Neoplasms; Neoplasms, Experimental; Pyrazines; Thiones; Thiophenes | 1993 |
Glutathione S-transferases--biomarkers of cancer risk and chemopreventive response.
Topics: Animals; Anticarcinogenic Agents; Biomarkers; Brassica; Colitis, Ulcerative; Colorectal Neoplasms; Disease Models, Animal; Enzyme Induction; Gene Expression; Glutathione Transferase; Humans; Inactivation, Metabolic; Mice; Neoplasms; Pyrazines; Risk Factors; Thiones; Thiophenes | 1998 |
Development of cancer chemopreventive agents: oltipraz as a paradigm.
Topics: Animals; Anticarcinogenic Agents; Chemoprevention; Cytochrome P-450 Enzyme System; Drug Approval; Enzyme Induction; Humans; Neoplasms; Pyrazines; Thiones; Thiophenes | 1999 |
Development of matrix metalloproteinase inhibitors in cancer therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Protease Inhibitors; Pyrazines; Sulfonamides; Tetracycline; Tetracyclines; Thiophenes | 2001 |
New agents in cancer clinical trials.
Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Isoquinolines; Lactams, Macrocyclic; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Rifabutin; Stilbenes; Tetrahydrofolates; Tetrahydroisoquinolines; Trabectedin; Vorinostat | 2000 |
The proteasome: a new target for novel drug therapies.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Lewis Lung; Clinical Trials, Phase I as Topic; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Disease Models, Animal; Humans; Multienzyme Complexes; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines | 2001 |
[Update on . . . the proteasome inhibitor PS341].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2002 |
Proteasome inhibition: a novel approach to cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2002 |
61 trial(s) available for pyrazines and Benign Neoplasms
| Article | Year |
|---|---|
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Female; Humans; Imidazoles; Male; Middle Aged; Models, Biological; Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyridines; Treatment Outcome | 2020 |
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Isoxazoles; Male; Middle Aged; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Pyrazines | 2021 |
Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzimidazoles; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Treatment Outcome | 2021 |
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Topics: Adolescent; Central Nervous System Neoplasms; Checkpoint Kinase 1; Checkpoint Kinase 2; Child; Child, Preschool; Female; Humans; Leukopenia; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Thrombocytopenia; Young Adult | 2021 |
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Axin Protein; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Pyridines; Treatment Outcome; Wnt Signaling Pathway | 2021 |
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2021 |
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Topics: Biomarkers, Tumor; Drug Monitoring; Female; Humans; Male; Molecular Targeted Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Treatment Outcome; Triazines | 2019 |
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome | 2013 |
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Leukocytes, Mononuclear; Neoplasms; Nuclear Receptor Subfamily 4, Group A, Member 1; Proto-Oncogene Proteins c-akt; Pyrazines; Time Factors; Transcription, Genetic; Vorinostat | 2013 |
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Tumor Burden | 2013 |
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Vorinostat | 2014 |
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Vorinostat; Young Adult | 2013 |
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; DNA; Female; Glutamates; Guanine; Humans; Male; Mice, Nude; Middle Aged; Neoplasms; Pemetrexed; Phenylurea Compounds; Pyrazines; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Young Adult | 2015 |
A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2015 |
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Checkpoint Kinase 1; Computer Simulation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Drug Interactions; Female; Humans; Infusions, Intravenous; Least-Squares Analysis; Male; Middle Aged; Neoplasms; Phenylurea Compounds; Protein Kinases; Pyrazines; Young Adult | 2015 |
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2015 |
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Food-Drug Interactions; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organic Chemicals; Pyrazines; Sulfonamides | 2015 |
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asian People; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Half-Life; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Response Evaluation Criteria in Solid Tumors; Sulfonamides | 2016 |
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.
Topics: Adult; Aged; Aged, 80 and over; Checkpoint Kinase 1; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2016 |
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Phenylurea Compounds; Pyrazines; Thrombocytopenia; Young Adult | 2016 |
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Thrombocytopenia | 2009 |
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Topics: Aged; Anti-Ulcer Agents; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Omeprazole; Proton Pump Inhibitors; Pyrazines | 2009 |
Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cetuximab; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; NF-kappa B; Pyrazines; Young Adult | 2009 |
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Paclitaxel; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2010 |
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
Topics: Antifungal Agents; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Prospective Studies; Pyrazines | 2009 |
Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Colorado; Combined Modality Therapy; Diarrhea; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Palliative Care; Pyrazines; Radiography | 2010 |
Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Pyrazines | 2010 |
Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasms; Pyrazines | 2011 |
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinases; Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome | 2011 |
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Fatigue; Female; Humans; Liver; Lymphopenia; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrazines; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Treatment Outcome; Young Adult | 2012 |
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Dosage Calculations; Female; Humans; Liver; Liver Diseases; Male; Middle Aged; Neoplasms; Pyrazines | 2012 |
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Female; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2013 |
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Hydroxamic Acids; Infant; Male; Maximum Tolerated Dose; Neoplasms; Pyrazines; Vorinostat; Young Adult | 2013 |
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Pyrroles; Sunitinib; Thyroid Neoplasms | 2013 |
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multienzyme Complexes; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Time Factors | 2002 |
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multienzyme Complexes; Neoplasms; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Statistics, Nonparametric | 2004 |
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
Topics: Biological Availability; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasms; Probability; Proportional Hazards Models; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; Risk Assessment; Salvage Therapy; Survival Rate; Treatment Outcome | 2004 |
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; I-kappa B Proteins; Male; Middle Aged; Nausea; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vomiting | 2005 |
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphoma; Male; Middle Aged; Neoplasms; Peripheral Nervous System; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2005 |
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Taxoids; Treatment Outcome | 2006 |
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2007 |
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2006 |
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Proteasome Inhibitors; Pyrazines | 2006 |
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2007 |
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Celecoxib; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Pyrazoles; Sulfonamides | 2007 |
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pemetrexed; Pyrazines; Survival Analysis | 2007 |
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Salvage Therapy; Treatment Outcome; Ubiquitination | 2008 |
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Polyethylene Glycols; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Treatment Outcome | 2008 |
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrazines | 2008 |
Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.
Topics: Adult; Aged; Antineoplastic Agents; Drug Tolerance; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Pyrazines | 1994 |
Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Neoplasms; Pyrazines | 1993 |
Determination of the anticancer agent CI-980 in plasma by achiral liquid chromatography on a Pirkle-type stationary phase.
Topics: Antineoplastic Agents; Carbamates; Child; Chromatography, Liquid; Humans; Neoplasms; Pyrazines; Pyridines; Sensitivity and Specificity; Stereoisomerism | 1997 |
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Carbamates; Central Nervous System Diseases; Drug Tolerance; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Pyridines | 1997 |
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Pyrazines; Pyridines; Thrombocytopenia | 1997 |
Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.
Topics: Administration, Oral; Area Under Curve; Dose-Response Relationship, Drug; Eating; Fasting; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasms; Postprandial Period; Protease Inhibitors; Pyrazines; Sulfonamides | 2000 |
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Quinolines; Thrombocytopenia; Vomiting | 2000 |
Oltipraz chemoprevention trial in Qidong, People's Republic of China: results of urine genotoxicity assays as related to smoking habits.
Topics: Administration, Oral; Adult; Biomarkers; Chemoprevention; Escherichia coli; Female; Humans; Male; Mutagenicity Tests; Mutagens; Neoplasms; Pyrazines; Reproducibility of Results; Salmonella typhimurium; Smoking; Thiones; Thiophenes; Urine | 2001 |
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Dose-Response Relationship, Drug; Exanthema; Female; Humans; Hydroxamic Acids; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Musculoskeletal Diseases; Nausea; Neoplasms; Protease Inhibitors; Pyrazines; Sulfonamides; Treatment Outcome | 2001 |
124 other study(ies) available for pyrazines and Benign Neoplasms
| Article | Year |
|---|---|
Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
Topics: Acetylation; Acetyltransferases; Enzyme Inhibitors; Histone Acetyltransferases; Histones; Humans; Lysine; Neoplasms; Pyrazines; Structure-Activity Relationship | 2022 |
A Patient-Derived Organoid Screen Identified the Bispecific Antibody MCLA-158.
Topics: Antibodies, Bispecific; Cell Proliferation; Humans; Imidazoles; Neoplasms; Organoids; Pyrazines | 2022 |
Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitor.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Maximum Tolerated Dose; Neoplasms; Pyrazines; Pyridines; Treatment Outcome | 2022 |
Mechanisms and inhibition of Porcupine-mediated Wnt acylation.
Topics: Acylation; Acyltransferases; Antineoplastic Agents; Binding Sites; Coenzyme A; Cryoelectron Microscopy; Histidine; Humans; Membrane Proteins; Neoplasms; Palmitoyl Coenzyme A; Pyrazines; Pyridines; Serine; Substrate Specificity; Wnt Signaling Pathway; Wnt3A Protein | 2022 |
A novel afterglow nanoreporter for monitoring cancer therapy.
Topics: Animals; Cell Line, Tumor; Mice; Nanoparticles; Neoplasms; Polymers; Pyrazines; Reactive Oxygen Species; Thiophenes | 2022 |
Single-molecule chemiluminescent photosensitizer for a self-activating and tumor-selective photodynamic therapy of cancer.
Topics: Cell Line, Tumor; Cell Survival; Computer Simulation; Humans; Imidazoles; Light; Neoplasms; Photochemotherapy; Photosensitizing Agents; Proof of Concept Study; Pyrazines; Singlet Oxygen; Thermodynamics | 2019 |
Activation of Piezo1 sensitizes cells to TRAIL-mediated apoptosis through mitochondrial outer membrane permeability.
Topics: Apoptosis; bcl-2-Associated X Protein; Humans; Intercellular Signaling Peptides and Proteins; Ion Channels; Mitochondrial Membranes; Models, Biological; Neoplasms; PC-3 Cells; Permeability; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Spider Venoms; Thiadiazoles; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2019 |
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Topics: Adenine; Animals; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Combined Modality Therapy; Cytokines; Cytotoxicity, Immunologic; Disease Models, Animal; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Mice; Neoplasms; Piperidines; Pyrazines; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; T-Lymphocytes; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxychloroquine; Immunosuppression Therapy; Kidney Diseases; Long QT Syndrome; Lopinavir; Neoplasms; Pandemics; Pneumonia, Viral; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach.
Topics: Benzamides; Healthy Volunteers; Humans; Models, Biological; Neoplasms; Pyrazines | 2022 |
Targeted Degradation of the Oncogenic Phosphatase SHP2.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Humans; Methanol; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proteolysis; Pyrazines; Signal Transduction | 2021 |
Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Gastric Mucosa; Haplorhini; Humans; Lung; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Quinolines; Rats; Rats, Sprague-Dawley; Stomach; Stomach Neoplasms | 2017 |
Synthesis of folate‑chitosan nanoparticles loaded with ligustrazine to target folate receptor positive cancer cells.
Topics: A549 Cells; Chitosan; Drug Liberation; Endocytosis; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Nanoparticles; Neoplasms; Proton Magnetic Resonance Spectroscopy; Pyrazines; Spectrophotometry, Infrared; Time Factors | 2017 |
Cytotoxicity, dual-targeting apoptosis induction evaluation of multinuclear cu complexes based on pyrazine-benzimidazole derivative.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Coordination Complexes; Copper; HCT116 Cells; Humans; Neoplasms; Pyrazines | 2018 |
Utilizing a Pyrazine-Containing Aggregation-Induced Emission Luminogen as an Efficient Photosensitizer for Imaging-Guided Two-Photon Photodynamic Therapy.
Topics: Cell Survival; Dynamic Light Scattering; Fluorescent Dyes; HeLa Cells; Humans; Infrared Rays; Microscopy, Electron, Transmission; Microscopy, Fluorescence, Multiphoton; Nanoparticles; Neoplasms; Photochemotherapy; Photons; Photosensitizing Agents; Pyrazines; Reactive Oxygen Species; Silicon Dioxide | 2018 |
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Checkpoint Kinase 1; Child; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Humans; Mice; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2019 |
Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Heterografts; Humans; Inflammation; MAP Kinase Kinase Kinases; Mice; Neoplasms; Protein Kinase Inhibitors; Pyrazines | 2019 |
Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytotoxicity, Immunologic; fas Receptor; Fusion Proteins, bcr-abl; Humans; Immunity, Innate; Immunotherapy; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Neoplasms; Pyrazines; RNA, Small Interfering | 2018 |
Identification of Factors Complicating Bioluminescence Imaging.
Topics: Adenosine Triphosphate; Animals; Enzyme Stability; Genes, Reporter; HEK293 Cells; HeLa Cells; Humans; Imidazoles; Luciferases; Luminescent Agents; Luminescent Measurements; Mice, Inbred BALB C; Neoplasms; Pyrazines; Tissue Distribution | 2019 |
Synthesis and structure-activity relationships of pyrazine-2-carboxamide derivatives as novel echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) inhibitors.
Topics: 3T3 Cells; Amides; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Binding Sites; Cell Cycle Proteins; Cell Line, Tumor; Humans; Mice; Microtubule-Associated Proteins; Molecular Docking Simulation; Neoplasms; Protein Structure, Tertiary; Pyrazines; Recombinant Fusion Proteins; Serine Endopeptidases; Solubility; Structure-Activity Relationship; Transplantation, Heterologous | 2019 |
Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Down-Regulation; Female; Gene Deletion; Mice; Mice, Inbred C57BL; Models, Molecular; Neoplasms; Proteasome Inhibitors; Pyrazines; STAT3 Transcription Factor; T-Lymphocytes, Cytotoxic; Tumor Suppressor Protein p53 | 2013 |
The clinical relevance of cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Transcriptome; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2013 |
[Proteasome inhibitors: from early stages to future prospects].
Topics: Animals; Boronic Acids; Bortezomib; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2012 |
Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Discovery; Humans; Immunoblotting; Neoplasms; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tetrazolium Salts; Thiazoles | 2013 |
Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; HIV Protease Inhibitors; Humans; Nelfinavir; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Pyrazines; TOR Serine-Threonine Kinases; Up-Regulation | 2013 |
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Doxorubicin; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Tumor Suppressor Protein p53 | 2014 |
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.
Topics: Acyltransferases; Animals; Axin Protein; Blotting, Western; Cell Line, Tumor; Cloning, Molecular; High-Throughput Screening Assays; Humans; Membrane Proteins; Mice; Mutagenesis; Neoplasms; Phosphorylation; Pyrazines; Pyridines; Radioligand Assay; Rats; Receptors, Notch; Reverse Transcriptase Polymerase Chain Reaction; Wnt Signaling Pathway | 2013 |
A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum Stress; Female; Genes, p53; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Piperidones; Proteasome Inhibitors; Pyrazines; Ubiquitination | 2013 |
Production of reactive oxygen and nitrogen species by light irradiation of a nitrosyl phthalocyanine ruthenium complex as a strategy for cancer treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coordination Complexes; Indoles; Isoindoles; Light; Mice; Neoplasms; Nitric Oxide; Photochemotherapy; Pyrazines; Pyridines; Ruthenium; Singlet Oxygen | 2014 |
Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Comet Assay; DNA Damage; Drug Design; Drug Synergism; Enzyme Inhibitors; Glutathione S-Transferase pi; Humans; Isoenzymes; Models, Molecular; Neoplasms; Nitric Oxide; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prodrugs; Pyrazines; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2014 |
Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Epidermal Growth Factor; HEK293 Cells; HeLa Cells; Humans; Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; STAT3 Transcription Factor; Tyrosine; Up-Regulation | 2014 |
Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors.
Topics: Administration, Intravenous; Aged; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Interactions; Feces; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Neoplasms; Phenylurea Compounds; Pyrazines; Tandem Mass Spectrometry | 2014 |
Bortezomib treatment causes long-term testicular dysfunction in young male mice.
Topics: Animals; Boronic Acids; Bortezomib; Follicle Stimulating Hormone; Humans; Male; Mice; Neoplasms; Proteasome Inhibitors; Pyrazines; Spermatogenesis; Testicular Diseases; Testis; Testosterone | 2014 |
ATR inhibition preferentially targets homologous recombination-deficient tumor cells.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Survival; Checkpoint Kinase 1; Drug Resistance, Neoplasm; HeLa Cells; Homologous Recombination; Humans; MCF-7 Cells; Molecular Targeted Therapy; Neoplasms; Protein Kinases; Pyrazines; Signal Transduction; Sulfones; Thiophenes; Urea | 2015 |
Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Gene Library; HEK293 Cells; Humans; Luminescent Proteins; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Array Analysis; Protein Interaction Maps; Proteolysis; Proto-Oncogene Proteins; Pyrazines; Transcriptome | 2014 |
A tale of two receptors: insulin and insulin-like growth factor signaling in cancer.
Topics: Antineoplastic Agents; Female; Humans; Imidazoles; Male; Neoplasms; Pyrazines | 2015 |
Amino acid derivatives of ligustrazine-oleanolic acid as new cytotoxic agents.
Topics: Antineoplastic Agents; Apoptosis; Cytotoxins; HeLa Cells; Hep G2 Cells; Humans; Neoplasms; Oleanolic Acid; Pyrazines; Structure-Activity Relationship; Vasodilator Agents | 2014 |
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Glycine; Hematologic Neoplasms; Humans; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin | 2015 |
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; HCT116 Cells; HEK293 Cells; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, SCID; Molecular Structure; Multiprotein Complexes; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrazines; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
Topics: Animals; Antineoplastic Agents; cdc25 Phosphatases; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Disease Models, Animal; DNA Damage; DNA Replication; Female; Humans; Mice; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrazoles; S Phase; Xenograft Model Antitumor Assays | 2015 |
Multimodality Imaging of Cancer Superoxide Anion Using the Small Molecule Coelenterazine.
Topics: Animals; Female; Flow Cytometry; HeLa Cells; Humans; Imidazoles; Mice, Inbred BALB C; Microscopy, Fluorescence; Multimodal Imaging; Neoplasms; Pyrazines; Small Molecule Libraries; Superoxides | 2016 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients.
Topics: Aged; Female; Humans; Imidazoles; Male; Metabolic Networks and Pathways; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazines | 2016 |
Radiosensitizing Effect of TRPV1 Channel Inhibitors in Cancer Cells.
Topics: Acrylamides; Anilides; Animals; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Capsaicin; Cell Line, Tumor; Cell Survival; Cinnamates; DNA Damage; Gamma Rays; Humans; Mice; Necrosis; Neoplasms; Pyrazines; Pyridines; Radiation-Sensitizing Agents; TRPV Cation Channels | 2016 |
Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Copepoda; Humans; Imidazoles; Luciferases; Luminescent Agents; Luminescent Measurements; Neoplasm Transplantation; Neoplasms; Phenylurea Compounds; Pyrazines; Quinolines; Recombinant Proteins; Treatment Outcome | 2016 |
T-3256336, a novel and orally available small molecule IAP antagonist, induced tumor cell death via induction of systemic TNF alpha production.
Topics: Administration, Oral; Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Survival; Cytokines; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Mice; Neoplasms; Oligopeptides; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Burden; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2016 |
A novel role for a familiar protein in apoptosis induced by proteasome inhibition.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Humans; Intracellular Signaling Peptides and Proteins; Necrosis; Neoplasms; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Time Factors; Up-Regulation | 2008 |
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; HCT116 Cells; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Necrosis; Neoplasms; Neovascularization, Pathologic; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; RNA Interference; RNA, Small Interfering; Time Factors; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
Productively combining proteasome inhibition with the immunotherapy of cancer.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; Drug Therapy, Combination; Humans; Immunotherapy; Models, Biological; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2008 |
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.
Topics: Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; HCT116 Cells; HSC70 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Kinetics; Lactams, Macrocyclic; Neoplasms; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Isoforms; Proto-Oncogene Proteins c-raf; Pyrazines; RNA, Small Interfering; Transfection; Ubiquitination | 2008 |
Proteasome inhibitors in pediatric cancer treatment.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Child; Humans; Leukemia; Neoplasms; Protease Inhibitors; Pyrazines | 2008 |
Deborah Dunsire.
Topics: Anti-Inflammatory Agents; Biopharmaceutics; Biotechnology; Boronic Acids; Bortezomib; Drug Industry; Entrepreneurship; History, 21st Century; Humans; Inflammation; Neoplasms; Organizational Objectives; Pyrazines | 2008 |
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Endoplasmic Reticulum; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Hydrazones; Hydroxyurea; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Transcription, Genetic; Ubiquitin | 2009 |
Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chymotrypsin; Cyclin-Dependent Kinase Inhibitor p27; Drug Discovery; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Neoplasms; Proteasome Inhibitors; Protein Conformation; Pyrazines; Serine Proteinase Inhibitors; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2009 |
Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cullin Proteins; Cyclopentanes; Humans; NEDD8 Protein; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrimidines; RING Finger Domains; Signal Transduction; Ubiquitin-Activating Enzymes; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases; Ubiquitins | 2009 |
From orbital hybridization to chemotherapeutics neutralization.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Interactions; Flavonoids; Humans; Molecular Structure; Neoplasms; Phenols; Plant Extracts; Polyphenols; Protease Inhibitors; Pyrazines; Tea | 2009 |
An audience with...Joseph Bolen. Interview by Bethan Hughes.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Drug Industry; Humans; Medical Oncology; Neoplasms; Pyrazines | 2009 |
GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib.
Topics: Angiogenesis Inhibitors; Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; MAP Kinase Signaling System; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Protein Folding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2009 |
Selectively killing transformed cells through proteasome inhibition.
Topics: Anthracyclines; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitination | 2009 |
Hydrogen peroxide is a second messenger in phase 2 enzyme induction by cancer chemopreventive dithiolethiones.
Topics: Animals; Antineoplastic Agents; Antioxidants; Cyclic N-Oxides; Diglycerides; Enzyme Induction; Hepatocytes; Humans; Hydrogen Peroxide; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Pyrazines; Second Messenger Systems; Thiones; Thiophenes | 2009 |
Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.
Topics: Antimalarials; Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; DNA-Binding Proteins; Heat Shock Transcription Factors; Heat-Shock Response; HeLa Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Neoplasms; Pyrazines; Quinacrine; RNA, Small Interfering; Transcription Factors | 2009 |
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Humans; Magnetic Resonance Imaging; Male; Metabolic Clearance Rate; Mice; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2009 |
Drug discovery and assay development in the ubiquitin-proteasome system.
Topics: Antineoplastic Agents; Biological Assay; Boronic Acids; Bortezomib; Drug Discovery; Drug Resistance, Neoplasm; Molecular Structure; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2010 |
Bortezomib: a new pro-apoptotic agent in cancer treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Dexamethasone; Humans; Mice; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Proteasome Inhibitors; Pyrazines | 2010 |
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; HCT116 Cells; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasms; Pyrazines; RNA, Small Interfering; Survivin | 2010 |
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Topics: Animals; Boron Compounds; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Screening Assays, Antitumor; Female; Glycine; HCT116 Cells; HT29 Cells; Humans; Lymphoma; Mice; Mice, SCID; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2010 |
Regulation of autophagy by ATF4 in response to severe hypoxia.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Base Sequence; Boronic Acids; Bortezomib; Cell Hypoxia; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; HeLa Cells; Humans; Neoplasms; Oligonucleotide Array Sequence Analysis; Oxygen; Pyrazines; RNA, Small Interfering; Tumor Cells, Cultured; Unfolded Protein Response; Validation Studies as Topic | 2010 |
γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Chromans; Enzyme Induction; G1 Phase; gamma-Tocopherol; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitor of Apoptosis Proteins; Janus Kinase 1; Janus Kinase 2; Mice; Neoplasm Proteins; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines; RNA, Small Interfering; src-Family Kinases; STAT3 Transcription Factor; Thalidomide; Vitamin E | 2010 |
Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
Topics: Antineoplastic Agents; Aurora Kinases; Cell Line, Tumor; Crystallography, X-Ray; Humans; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Structure-Activity Relationship | 2010 |
Continual reassessment method with multiple toxicity constraints.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Clinical Trials, Phase I as Topic; Computer Simulation; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epidemiologic Research Design; Humans; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Models, Statistical; Neoplasms; Neurotoxicity Syndromes; Prednisolone; Probability; Pyrazines; Statistical Distributions; Thrombocytopenia; Vincristine | 2011 |
Amino acid starvation sensitizes cancer cells to proteasome inhibition.
Topics: Amino Acids; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cells, Cultured; Humans; Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retinoblastoma Protein; Tumor Suppressor Protein p53 | 2010 |
Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Imidazoles; Mice; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Structure-Activity Relationship; Transplantation, Heterologous | 2011 |
Myc overexpression brings out unexpected antiapoptotic effects of miR-34a.
Topics: ADP-Ribosylation Factors; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; MicroRNAs; Neoplasms; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins c-myc; Pyrazines; Tumor Suppressor Protein p53 | 2011 |
SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Cell Line, Tumor; Drug Administration Schedule; Female; Humans; Imidazoles; Kinesins; Male; Mice; Mice, Nude; Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Taxoids; Xenograft Model Antitumor Assays | 2011 |
Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; HCT116 Cells; Humans; Neoplasms; Pyrazines; Thiazoles; Thiostrepton | 2011 |
Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.
Topics: Animals; Antineoplastic Agents; Cell Line; Female; Humans; Imidazoles; Mice; Mice, Nude; Microsomes; Models, Molecular; Molecular Structure; Neoplasms; Protein Conformation; Pyrazines; Rats; Rats, Sprague-Dawley; Receptor, IGF Type 1; Receptor, Insulin; Xenograft Model Antitumor Assays | 2009 |
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Female; Humans; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2011 |
Toxicity burden score: a novel approach to summarize multiple toxic effects.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Health Status Indicators; Humans; Neoplasms; Pyrazines; Toxicity Tests | 2012 |
Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part
Topics: Animals; Antineoplastic Agents; Dogs; Hedgehog Proteins; Humans; Imidazoles; Mice; Neoplasms; Pyrazines; Rats; Signal Transduction; Stereoisomerism; Structure-Activity Relationship | 2011 |
Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 1
Topics: Antineoplastic Agents; Hedgehog Proteins; Humans; Imidazoles; Neoplasms; Pyrazines; Signal Transduction; Structure-Activity Relationship | 2011 |
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
Topics: Animals; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; Neoplasms; Proteasome Inhibitors; Protein Folding; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Escape | 2011 |
Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Discovery; Humans; Models, Molecular; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Structure-Activity Relationship; TOR Serine-Threonine Kinases | 2011 |
Molecular pathways: targeting proteasomal protein degradation in cancer.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Signal Transduction; Ubiquitin | 2012 |
Targeting proteasomal protein degradation in cancer-letter.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Humans; Neoplasms; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin | 2012 |
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Imidazoles; Mice; Microsomes, Liver; Models, Molecular; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction | 2012 |
Proteasomal insensitivity of apoptin in tumor cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Capsid Proteins; Cell Line; Cell Line, Tumor; Fibroblasts; Humans; Mutation; Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; Pyrazines; Tumor Suppressor Protein p53 | 2012 |
Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Fluid; Humans; Male; Mice; Mice, Nude; Neoplasms; Pyrazines; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Female; Genes, Reporter; Green Fluorescent Proteins; HEK293 Cells; Humans; Mice; Mice, Nude; Molecular Imaging; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2012 |
Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
Topics: Administration, Oral; Animals; Apoptosis; Cell Line, Tumor; Cytochromes; Disease Models, Animal; Half-Life; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Microsomes, Liver; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrazines; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2012 |
Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
Topics: Acetamides; Animals; Benzoquinones; Blotting, Western; Cell Line, Tumor; Drug Discovery; High-Throughput Screening Assays; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Immunoprecipitation; Intramolecular Oxidoreductases; Lactams, Macrocyclic; Lead; Luciferases, Firefly; Luciferases, Renilla; Mice; Mice, Nude; Neoplasms; Positron-Emission Tomography; Prostaglandin-E Synthases; Protein Folding; Protein Isoforms; Pyrazines; Small Molecule Libraries; Thioacetamide; Thiophenes; Tomography, X-Ray Computed; Tritium | 2012 |
[Proteasome oncology: pioneer a new field in drug development].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2012 |
The first total synthesis and biological evaluation of marine natural products ma'edamines A and B.
Topics: Animals; Biological Products; Cell Line, Tumor; Comet Assay; Humans; MCF-7 Cells; Neoplasms; Porifera; Pyrazines | 2013 |
[Perspectives on the oncologist pharmacopoeia].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin | 2003 |
Clinical trials referral resource. Current clinical trials of bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; National Institutes of Health (U.S.); Neoplasms; Patient Selection; Protease Inhibitors; Pyrazines; United States | 2003 |
Can smart bombs win the war on cancer? By pinpointing abnormalities specific to tumor cells, a novel generation of cancer drugs may usher in a whole new era of cancer treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Enzyme Inhibitors; Humans; Neoplasms; Protease Inhibitors; Protein-Tyrosine Kinases; Pyrazines | 2003 |
Molecule of the month. Bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; National Institutes of Health (U.S.); Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; United States | 2003 |
Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz.
Topics: Aflatoxin B1; Animals; Anticarcinogenic Agents; Antioxidants; Blotting, Western; Carcinogens; DNA; DNA Adducts; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Glutathione Transferase; Immunoblotting; Liver; Male; Models, Chemical; Neoplasms; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Pyrazines; Rats; Rats, Inbred F344; RNA; RNA, Messenger; Temperature; Thiones; Thiophenes; Time Factors | 2003 |
Combinations of targeted therapies take aim at multiple pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Research Design | 2003 |
"Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.
Topics: Biomedical Research; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Industry; Federal Government; Humans; Interinstitutional Relations; Neoplasms; Protease Inhibitors; Pyrazines | 2004 |
[Proteasome inhibitors--new option in the treatment of tumor diseases].
Topics: Animals; Boronic Acids; Bortezomib; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2004 |
[Bortezomib in second-line therapy].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasms; Pyrazines; Randomized Controlled Trials as Topic | 2005 |
The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Ligands; Membrane Glycoproteins; Neoplasms; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2005 |
A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.
Topics: Anticarcinogenic Agents; Clinical Trials as Topic; Computer Simulation; Humans; Models, Statistical; Monte Carlo Method; Neoplasms; Pyrazines; Sample Size; Thiones; Thiophenes | 2006 |
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Depsipeptides; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Killer Cells, Natural; Membrane Glycoproteins; Neoplasms; Protease Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2006 |
Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress.
Topics: Apoptosis; Boronic Acids; Bortezomib; Endoplasmic Reticulum; Humans; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2006 |
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Dendritic Cells; Gamma Rays; HSP90 Heat-Shock Proteins; Humans; Interferon-gamma; Lactams, Macrocyclic; Leukocytes, Mononuclear; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines | 2007 |
Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cells, Cultured; Cytokines; Dendritic Cells; Humans; Immunity; Killer Cells, Natural; Neoplasms; Protease Inhibitors; Pyrazines | 2007 |
Interactions of the major metabolite of the cancer chemopreventive drug oltipraz with cytochrome c: a novel pathway for cancer chemoprevention.
Topics: Animals; Anticarcinogenic Agents; Antioxidants; Chemoprevention; Cytochromes c; Electron Spin Resonance Spectroscopy; Electron Transport; Heart; Horses; Mass Spectrometry; Mitochondria; Neoplasms; Oxidation-Reduction; Peroxidase; Pyrazines; Reactive Oxygen Species; Spectrophotometry, Ultraviolet; Thiones; Thiophenes | 2007 |
Management of comorbid diabetes and cancer.
Topics: Ambulatory Care; Amyloid; Comorbidity; Diabetes Mellitus; Exenatide; Humans; Hypoglycemic Agents; Inpatients; Insulin; Islet Amyloid Polypeptide; Neoplasms; Peptides; Practice Guidelines as Topic; Pyrazines; Quality of Life; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2007 |
Proteasome inhibition therapies in childhood cancer.
Topics: Animals; Bone Development; Boronic Acids; Bortezomib; Child; Chondrocytes; Humans; Mice; Neoplasms; Protease Inhibitors; Pyrazines | 2008 |
Fold up or perish: unfolded protein response and chemotherapy.
Topics: Anilides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Endoplasmic Reticulum; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Folding; Pyrazines | 2008 |
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Endothelial Cells; Enzyme Inhibitors; Humans; Macrophage Colony-Stimulating Factor; Mice; Mice, Nude; Multiple Myeloma; Neoplasms; NF-kappa B; Osteogenesis; Proteasome Inhibitors; Pyrazines; RANK Ligand; Threonine; Treatment Outcome; Ubiquitin; Xenograft Model Antitumor Assays | 2008 |
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytotoxicity, Immunologic; Fas Ligand Protein; Immunotherapy; Killer Cells, Natural; Leukemia; Mice; Mice, Inbred Strains; Neoplasms; Perforin; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2008 |
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.
Topics: Adaptation, Biological; Boronic Acids; Bortezomib; Cell Hypoxia; Cell Line; DNA-Binding Proteins; Humans; Hypoxia-Inducible Factor 1; Mixed Function Oxygenases; Neoplasms; p300-CBP Transcription Factors; Pyrazines; Repressor Proteins; Trans-Activators; Transcription Factors; Transcription, Genetic | 2008 |
Revealing targeted therapy for human cancer by gene module maps.
Topics: Algorithms; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Chromosome Mapping; Electronic Data Processing; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gene Targeting; Genes, Mitochondrial; Genetic Therapy; Humans; Neoplasm Invasiveness; Neoplasms; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Wounds and Injuries | 2008 |
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Humans; Lactones; Neoplasms; NF-kappa B; Protease Inhibitors; Pyrazines; Pyrroles; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Up-Regulation; YY1 Transcription Factor | 2008 |
Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells.
Topics: Animals; Antineoplastic Agents; Biotransformation; Cytochrome Reductases; Cytochrome-B(5) Reductase; Female; Humans; Hydroxymercuribenzoates; Mice; Mice, Inbred C3H; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Pyrazines; Reproducibility of Results; Spectrophotometry; Tumor Cells, Cultured | 1996 |
CGS 27023A. CDG 27023A.
Topics: Animals; Antineoplastic Agents; Antirheumatic Agents; Drugs, Investigational; Humans; Hydroxamic Acids; Metalloendopeptidases; Mice; Neoplasms; Protease Inhibitors; Pyrazines; Rabbits; Rats; Rheumatic Diseases; Sulfonamides | 1999 |
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Topics: Acetylcysteine; Acrylates; Amino Acid Chloromethyl Ketones; Apoptosis; Boronic Acids; Bortezomib; Calpain; Cathepsins; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Drug Synergism; Genes, p53; Humans; Jurkat Cells; Leupeptins; Multienzyme Complexes; Neoplasm Proteins; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; U937 Cells | 2000 |
Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hematologic Neoplasms; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2000 |
Synthesis of 2-(allylthio)pyrazines as a novel cancer chemopreventive agent.
Topics: Anticarcinogenic Agents; Enzyme Inhibitors; Neoplasms; Pyrazines | 2001 |
Cancer research. Taking garbage in, tossing cancer out?
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Multiple Myeloma; Neoplasm Proteins; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines | 2002 |
Oltipraz protects the passive smoke induced changes in renal glyoxalase system of rats.
Topics: Animals; Anticarcinogenic Agents; Female; Kidney; Lactoylglutathione Lyase; Neoplasms; Pyrazines; Rats; Rats, Sprague-Dawley; Thiolester Hydrolases; Thiones; Thiophenes; Tobacco Smoke Pollution | 2002 |
Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.
Topics: Animals; Antineoplastic Agents; Drug Administration Schedule; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Neoplasms; Pyrazines; Tumor Cells, Cultured | 1990 |